Logo

Fresenius Medical Care’s 5008X Hemodialysis System Receives the US FDA’s 510(k) Clearance as a Dialysis Therapy for Kidney Disease Patients

Share this
Fresenius Medical Care

Fresenius Medical Care’s 5008X Hemodialysis System Receives the US FDA’s 510(k) Clearance as a Dialysis Therapy for Kidney Disease Patients

Shots:

  • The clearance was granted to 5008X Hemodialysis System, a high-volume hemodiafiltration dialysis therapy, based on the results from the  (CONVINCE) multinational research study comparing 5008X Hemodialysis System vs conventionally used hemodialysis techniques for a duration of 3yrs. across 61 dialysis centers in 8 European countries
  • The results from the study depicted that patients treated with high-volume hemodiafiltration experienced a 23% decrease in mortality rates vs those treated with conventional high-flux hemodialysis
  • The clearance allows the company to initiate a clinical evaluation and user studies across the US with an expected commercial launch of 5008X Hemodialysis System by 2025

Ref: PR Newswire | Image: Fresenius Medical Care

Related News:- Fresenius Medical Care Recalls Few Models of Haemodialysis Machines for Potential Exposure to Toxic Substances in the US

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions